Recently, Tumor Immune Cell Targeting Chimera (TICTACs) were developed by the group of Prof. Carolyn Bertozzi, in which antibodies specific for immune checkpoint are conjugated to a ligand for CD206, a TAM marker [67]. Here, MRC1 is linked to neoplasm.